Biopharmaceutical contract development and manufacturing organization (CDMO) NorthX Biologics is pleased to announce the appointment of Patrik DePalma as Senior Vice President of Business Development in North America.
With over 30 years of experience in the pharmaceutical industry, Patrick brings a wealth of expertise in Research & Development, Quality Assurance, and Business Development, particularly in the CDMO space with a focus on complex biologics and advanced therapies.
Patrick has held pivotal leadership roles at renowned organizations, including Emergent, Vigene/Charles River, and Advaxia Biologics, where he drove business growth and forged strategic partnerships. His academic credentials include a Bachelor of Science (ACS-accredited) and a Master of Science in Analytical Chemistry (LC/MS) from Clemson University.
Janet Hoogstraate, CEO NorthX Biologics comments: “I am delighted to welcome Patrick to our team as we accelerate our growth journey, particularly in new markets like North America. His impressive track record and deep industry knowledge will undoubtedly strengthen our commercial team and enhance our ability to serve clients worldwide.”
Patrick DePalma expressed his enthusiasm for joining NorthX Biologics, saying: "NorthX Biologics offers an outstanding portfolio of services, from microbial and mammalian recombinant proteins to viral products, mRNA, plasmids, cell therapy, and extracellular vesicles. The company’s reputation as a trusted partner and its commitment to its ‘Beyond CDMO’ approach make this an exciting time to join. I look forward to collaborating with the team to support our clients in delivering life-changing therapies to patients globally."
This strategic appointment underscores NorthX Biologics’ commitment to expanding its global reach and delivering cutting-edge solutions in the biopharmaceutical industry.
About NorthX Biologics
NorthX Biologics is a CDMO and Innovation Hub in Advanced Biologics, with +30 years of GMP production experience. The team provides process development and GMP manufacturing services with expertise in plasmid DNA, mRNA, proteins, cells and other advanced biologics. Headquartered in the heart of Sweden, the team serves customers worldwide and in 2021 was recognized as a national innovation hub for advanced therapeutics and vaccines.
For more information see www.nxbio.com.
Media inquiries
Please contact CEO Janet Hoogstraate
